论文部分内容阅读
目的分析消化道肿瘤患者内源性促红细胞生成素水平及贫血状态,探讨使用重组人促红细胞生成素治疗消化道肿瘤相关性贫血的方案.方法内源性促红细胞生成素采用Elisa检测,血红蛋白采用常规检测.消化道肿瘤非贫血患者为对照组,消化道肿瘤贫血患者组为观察组.结果统计发现男女之间的贫血率没有差异,消化道肿瘤相关性贫血患者占38.95%,其中以胃癌居首,占42.2%,食管鳞癌最低,占35.6%.消化道肿瘤患者在化疗前贫血比非贫血患者EPO高而Hb低,两者存在逆相关关系,化疗后贫血患者Hb继续降低,EPO上升;而在化疗后非贫血患者中出现的26例贫血患者,其中16例出现EPO急剧上升,10例EPO几乎不变,EPO存在极显著差异,具有统计学意义,而Hb没有明显的差异.结论消化道肿瘤相关性贫血发生率较高,在临床治疗中要密切关注.
Objective To analyze the level of endogenous erythropoietin and anemia in patients with digestive tract tumors and to investigate the use of recombinant human erythropoietin in the treatment of gastrointestinal cancer-related anemia. Methods Endogenous erythropoietin was detected by Elisa and hemoglobin was used. Routine tests. Patients with non-anaemia of digestive tract tumors were control group. Patients with anemia of digestive tract tumors were observed groups. The results showed that there was no difference in anemia between men and women. Gastrointestinal tumor-related anemia accounted for 38.95% of patients. The first, accounting for 42.2%, the lowest esophageal squamous cell carcinoma, accounting for 35.6%. Anemia before chemotherapy in patients with gastrointestinal cancer than non-anemic patients with high EPO and low Hb, there is an inverse correlation between the two, after chemotherapy anemia patients continue to decrease Hb, EPO rose However, in the 26 patients with anemia after chemotherapy, there were 26 patients with anemia, of which 16 cases showed a sharp increase in EPO, 10 cases of EPO almost unchanged, there was a very significant difference in EPO, with statistical significance, and Hb had no significant difference. The incidence of anaemia associated with digestive tract tumors is high, and we must pay close attention in clinical treatment.